E. Ferrannini

Endocrinology, Diabetes and Metabolism · 2005–2017

A researcher in the Science corpus: 20 papers; trusts 4 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Endocrinology, Diabetes and Metabolism — 223 citations into it; #457 of 623 by trust here, #69 by citations
• Surgery — 79 citations into it; #914 of 1,106 by trust here, #564 by citations
• Epidemiology — 68 citations into it

Whom E. Ferrannini trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Silvio E. Inzucchi
2. M. Murphy
3. P. Ridker
4. Rury R. Holman
5. D. Nathan

Who trusts E. Ferrannini overall

1. Patrycja Puchalska
2. Lawrence Lin
3. P. Crawford
4. M. Levine
5. G. Lopaschuk
6. S. Verma

Papers from E. Ferrannini's perspective

Ordered by how strongly the researchers E. Ferrannini trusts endorse each paper. Same corpus, a different order for every researcher.

1. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study (British medical journal)
2. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (The Lancet)
3. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. (Cochrane Database of Systematic Reviews)
4. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (Diabetes Care)
5. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes… (Diabetes Care)
6. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. (New England Journal of Medicine)
7. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. (Circulation)
8. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta‐analysis of controlled clinical trials (Journal of the American Medical Association (JAMA))
9. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. (Journal of the American Medical Association (JAMA))
10. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3… (The Lancet)

Their papers

• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) — 2,670 citations
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014) — 2,951 citations
• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis (2016) — 905 citations
• Type 2 diabetes mellitus (2015) — 2,875 citations
• How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017) — 631 citations
• Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes (2016) — 637 citations
• Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors (2015) — 619 citations
• Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015) — 732 citations
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. (2014) — 987 citations
• Defining the role of common variation in the genomic and biological architecture of adult human height (2014)
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 (2013) — 1,101 citations
• Diabetes and hypertension: the bad companions. (2012) — 604 citations
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012) — 3,782 citations
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise (2010) — 750 citations
• α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population (2010) — 664 citations
• Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008) — 751 citations
• Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. (2007) — 607 citations
• Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms (2005) — 750 citations
• Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. (2005) — 768 citations
• The metabolic syndrome: time for a critical appraisal (2005) — 2,364 citations